Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Onychomycosis Treatment Market Growth From $4.16 Billion In 2026 To $5.51 Billion By 2030 At A CAGR Of 7.3%
The market for onychomycosis therapies has experienced robust expansion lately, projected to increase from $3.91 billion in 2025 to $4.16 billion in 2026, reflecting a compound annual growth rate of 6.5%. This upward trend during the preceding period was fueled by several factors, including a high incidence of onychomycosis, a scarcity of sophisticated antifungal medications, heightened consciousness regarding nail cleanliness, escalating demand for topical antifungal solutions, and a greater prevalence of fungal infections among the elderly demographic.
The market for onychomycosis treatments is poised for significant expansion over the coming years, projected to reach $5.51 billion by 2030, fueled by a compound annual growth rate of 7.3%. This anticipated surge is largely driven by innovations in laser and photodynamic therapies, a growing preference for combined treatment strategies, an increased utilization of remote dermatology consultations, broader accessibility through hospital and retail pharmacy networks, and ongoing research efforts targeting drug-resistant fungal varieties. Key developments expected during this timeframe include a greater embrace of therapeutic regimens that blend medication with laser treatments, expanded application of photodynamic therapy for persistent infections, heightened public consciousness regarding proactive nail health, the integration of artificial intelligence within diagnostic tools for fungal conditions, and a continued rise in telehealth services for managing onychomycosis.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp
Onychomycosis Treatment Market Industry Drivers: What Is Driving Revenue Growth?
The rising incidence of fungal infections is poised to stimulate expansion within the onychomycosis treatment sector. Fungal infections, identified as illnesses stemming from diverse fungi, can manifest in various bodily regions or result in distinct ailments. Onychomycosis, specifically a fungal infection affecting the nails, is commonly addressed through oral antifungal drugs or topical antifungal preparations aimed at eradicating the root fungal cause and encouraging the return of healthy nail development. Illustrating this trend, the UK Health Security Agency reported in May 2025 that bloodstream infections attributed to yeasts in England saw a 31% surge from 2015 levels and a 4% increase compared to 2023 data from the year 2024. Moreover, the period between 2023 and 2024 witnessed a 4% rise in laboratory notifications of fungemia caused by yeasts in England, escalating from 2,170 to 2,247 reports. Consequently, the escalating prevalence of fungal infections is acting as a catalyst for the growth of the onychomycosis treatment market.
Onychomycosis Treatment Market Segment Analysis Highlighting Growth Areas
The onychomycosis treatment market covered in this report is segmented –
1) By Type: Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis, Other Types
2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy
3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
#Onychomycosis Treatment Market Growth Trends: What Is Influencing The Future Outlook?
In the realm of the onychomycosis treatment market, leading pharmaceutical firms are strategically concentrating their efforts on innovating and securing regulatory endorsements for novel therapies, like MOB-015, as a means to solidify their market standing. A prime illustration of this trend is Moberg Pharma AB, a Swedish entity, which successfully obtained European Union authorization in June 2023 for MOB-015, a treatment intended for adult nail fungal infections of mild to moderate severity. This European approval signifies the pioneering onychomycosis drug’s inaugural international go-ahead for commercialization. Evidence from two pivotal Phase 3 studies, which underpinned the approval, revealed a significantly enhanced mycological cure rate (76% compared to a maximum of 42% for control groups) and a markedly superior overall cure rate compared to the placebo, all while maintaining an excellent safety profile free from serious adverse events. MOB-015, a topical terbinafine preparation, ensures that therapeutically effective levels of terbinafine penetrate the nail and nail bed, circumventing the systemic risks inherent in oral terbinafine administration.
Onychomycosis Treatment Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd.
Access The Complete Onychomycosis Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report
Onychomycosis Treatment Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the onychomycosis treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
